Next Article in Journal
Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Previous Article in Journal
L-Lysine as the Molecule Influencing Selective Brain Activity in Pain-Induced Behavior of Rats
Previous Article in Special Issue
In Vitro Assessment of Bioactive Glass Coatings on Alumina/Zirconia Composite Implants for Potential Use in Prosthetic Applications
Open AccessArticle

FK506 Induces Ligand-Independent Activation of the Bone Morphogenetic Protein Pathway and Osteogenesis

Atlanta VA Medical Center, Decatur, GA 30033, USA
Department of Orthopaedics, Emory University School of Medicine, Atlanta, GA 30322, USA
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(8), 1900;
Received: 29 March 2019 / Revised: 12 April 2019 / Accepted: 12 April 2019 / Published: 17 April 2019
(This article belongs to the Special Issue Biomaterials for Bone Tissue Engineering)
Osteoinductive bone morphogenetic proteins (BMPs), including BMP-2, have a unique capability of mediating bone formation both in orthotopic and ectopic locations. Immunosuppresive macrolides have been shown to potentiate BMP-2 activity through FKBP12, but these have yet to translate to effective osteoinductive therapies. Herein, we show the osteogenic activity of FK506 as a stand-alone agent in direct comparison to BMP-2 both in vitro and in vivo. FK506 was capable of producing stand-alone alkaline phosphatase induction in C2C12 cells comparable to that seen with rhBMP-2. FK506 treatment activated the BMP receptor, as shown by increased pSmad1/5 levels, and produced significantly higher mRNA levels of the early response genes in BMP and TGF-β pathways. Additionally, the FK506 induction of alkaline phosphatase was shown to be resistant to Noggin treatment. In vivo osteogenic activity of FK506 was tested by local delivery on a collagen sponge in an ectopic subcutaneous implantation model in the rat. Dose responses of FK506 showed increasing levels of ectopic mineralization comparable to the mineral volume produced by BMP-2 delivery. These findings suggest that the use of FK506 can enhance osteoblastic differentiation in vitro and can induce mineralization when delivered locally in vivo. View Full-Text
Keywords: BMP-2; tacrolimus; osteogenesis; small molecule BMP-2; tacrolimus; osteogenesis; small molecule
Show Figures

Graphical abstract

MDPI and ACS Style

Sangadala, S.; Devereaux, E.J.; Presciutti, S.M.; Boden, S.D.; Willet, N.J. FK506 Induces Ligand-Independent Activation of the Bone Morphogenetic Protein Pathway and Osteogenesis. Int. J. Mol. Sci. 2019, 20, 1900.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop